B
Bullisch
Bullisch · 25%IMTX
$9.47
Szenariopreis
$7.140
+0.143 (+2.00%)Zum Schluss
Loading chart…
- Hoch
- 7.210
- Eröffnung
- 7.050
- Volumengewichteter Durchschnittskurs
- 7.10
- Volumen
- 1.63M
- Marktkap.
- 1.22B
- Tief
- 6.948
- Umsatz
- 11.57M
- EV/EBITDA, TTM
- -3.03
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
KI-Analyse of Immatics NV (IMTX)
HaltenImmatics NV (IMTX) is currently not a strong buy due to its low RSI of 25.722, indicating oversold conditions, and a significant year-to-date price drop of 28.90%. While the company is raising $150 million to strengthen its financial position, the recent performance and negative earnings trends present considerable risks.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Immatics NV (IMTX) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -1.40.
Alphio-AI-Kursszenarien für IMTX
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die IMTX halten
Event-Zeitleiste
News
4.508-25Yahoo FinanceHealthcare Stocks Edge Higher Premarket
8.508-25NASDAQ.COMImmatics N.V. to Raise $150 Million Through Public Offering
8.507-17NewsfilterImmatics to Present PRAME Therapy Data at ESMO Congress
- 9.005-31Newsfilter
Immatics Reports Promising IMA401 Clinical Data
9.505-12seekingalphaImmatics Reports Q1 2023 Financial Results
IMTX FAQ – beantwortet von Alphio AI
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Immatics NV (IMTX) is currently not a strong buy due to its low RSI of 25.722, indicating oversold conditions, and a significant year-to-date price drop of 28.90%. While the company is raising $150 million to strengthen its financial position, the recent performance and negative earnings trends present considerable risks.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.